Abstract
In the aftermath of the 2015 pandemic of Zika virus, concerns over links between climate change and emerging arboviruses have become more pressing. Given the potential that much of the world might remain at risk from the virus, we use a model of thermal bounds on Zika virus (ZIKV) transmission to project climate change impacts on transmission suitability risk by mid-century (a generation into the future). In the worst-case scenario, over 1.3 billion new people could face suitable transmission temperatures for ZIKV by 2050. Given these suitability risk projections, we suggest an increased priority on research establishing the immune history of vulnerable populations, modeling when and where the next ZIKV outbreak might occur, evaluating the efficacy of conventional and novel intervention measures, and increasing surveillance efforts to prevent further expansion of ZIKV.
Author Summary First discovered in Uganda in the 1950s, Zika virus (ZIKV) is a new threat to global health security. The virus is spread primarily by female Aedes mosquitoes, with occasional sexual transmission in humans, and can cause Zika congenital syndrome (which includes fetal abnormalities like microcephaly) when women are infected during pregnancy. Our study is the first to quantify how many people may be exposed to temperatures suitable for ZIKV transmission in a changing climate. In the worst-case scenario, by 2050, climate change could expose more than 1.3 billion people worldwide to temperatures suitable for transmission - for the first time. The next generation will face substantially increased ZIKV transmission temperature suitability in North America and Europe, where naïve populations might be particularly vulnerable. Mitigating climate change even to moderate emissions scenarios could significantly reduce global expansion of climates suitable for ZIKV transmission, potentially protecting around 200 million people.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SJR, LRJ, and EAM were supported by NSF EEID (DEB-1518681), EAM, CCM, BT, MHB and CNN were supported by the National Science Foundation, Grants for Rapid Response Research (NSF-RAPID 1640780). EAM was additionally supported by the NIH (1R35GM133439-01), the Terman Award, the Helman Scholarship, and a Stanford University King Center for Global Development Seed Grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
n/a
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Mapped results will be available through Harvard Dataverse at publication acceptance through URL XXX-XXX
